Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.81)
# 3,134
Out of 4,876 analysts
108
Total ratings
27%
Success rate
-6.67%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XGN Exagen | Maintains: Overweight | $8 → $7 | $7.00 | - | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.17 | +70.94% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $10.77 | +57.85% | 6 | May 14, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $18.12 | +37.97% | 9 | May 6, 2025 | |
| NNOX Nano-X Imaging | Maintains: Overweight | $12 → $9 | $5.29 | +70.29% | 11 | Apr 1, 2025 | |
| SMTI Sanara MedTech | Reiterates: Overweight | $46 | $28.45 | +61.69% | 6 | Mar 26, 2025 | |
| ELUT Elutia | Reiterates: Overweight | $8 | $1.85 | +332.43% | 10 | Mar 7, 2025 | |
| AXGN Axogen | Reiterates: Overweight | $24 | $10.43 | +130.22% | 3 | Mar 5, 2025 | |
| MDXG MiMedx Group | Reiterates: Overweight | $13 | $5.91 | +119.97% | 3 | Feb 27, 2025 | |
| CERS Cerus | Reiterates: Overweight | $4 | $1.34 | +199.63% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $9 | $8.69 | +3.57% | 7 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.13 | +118.18% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $5.25 | +300.38% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $7.60 | +110.53% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $5.88 | +138.10% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $96 | $82.53 | +16.32% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.27 | +175.59% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.86 | +192.40% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.38 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.56 | +40.45% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.59 | +1,354.15% | 2 | Aug 18, 2023 |
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $7.00
Upside: -
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.17
Upside: +70.94%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $10.77
Upside: +57.85%
SI-BONE
May 6, 2025
Reiterates: Overweight
Price Target: $25
Current: $18.12
Upside: +37.97%
Nano-X Imaging
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $5.29
Upside: +70.29%
Sanara MedTech
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $28.45
Upside: +61.69%
Elutia
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.85
Upside: +332.43%
Axogen
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $10.43
Upside: +130.22%
MiMedx Group
Feb 27, 2025
Reiterates: Overweight
Price Target: $13
Current: $5.91
Upside: +119.97%
Cerus
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.34
Upside: +199.63%
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $8.69
Upside: +3.57%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $4.13
Upside: +118.18%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $5.25
Upside: +300.38%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $7.60
Upside: +110.53%
Oct 23, 2024
Reiterates: Overweight
Price Target: $14
Current: $5.88
Upside: +138.10%
Oct 15, 2024
Initiates: Neutral
Price Target: $96
Current: $82.53
Upside: +16.32%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.27
Upside: +175.59%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.86
Upside: +192.40%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Mar 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.56
Upside: +40.45%
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.59
Upside: +1,354.15%